Showing posts with label CO Pub Rel: Gilead. Show all posts
Showing posts with label CO Pub Rel: Gilead. Show all posts

Friday, May 02, 2008

Off to Phase IV for Letairis® and the Market for Volibris®


Among the core assets that Gilead (Nasdaq: GILD) acquired from Myogen in 2006 for $2.5B was Letairis® (ambrisentan), for the treatment of pulmonary arterial hypertension (PAH), which was then approved by the FDA in mid 2007. After about a quarter in the market Gilead has initiated a Phase IV, randomized, double-blind, placebo-controlled study evaluating Letairis® in patients with PAH who have failed to demonstrate an optimal response to sildenafil monotherapy (Viagra® is not just for ED ya know…). The primary endpoint of this study, known as Athena-1, is the change from baseline in pulmonary vascular resistance (the resistance to blood flow caused by constricted lung blood vessels) following 24 weeks of treatment. The long-term safety and efficacy measures will be examined for up to one year. There are additional planned follow-on Phase IV studies through 2009.

Folks around town may recall that GlaxoSmithKline (NYSE: GSK) owns the rights to commercialize ambrisentan for PAH in territories outside of the US. Recently GSK announced that the European Commission issued a marketing authorization for ambrisentan, under the trade name Volibris®, for the treatment of PAH in patients to improve exercise capacity, and the European product launch is now scheduled for 3Q08. Very exciting global news that can trace its roots back to Colorado! Naturally we will be closely tracking performance of Letairis® and Volibris® in the coming months and years

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Friday, February 29, 2008

Michael Bristow, M.D., Ph.D. Wins 2008 PhRMA Award


Congratulations to Michael Bristow, M.D., Ph.D., the S. Gilbert Blount Professor of Medicine at University of Colorado, Head of Cardiology, Co-director of the University of Colorado Cardiovascular Institute, co-founder of Myogen (acquired by Gilead (NASDAQ: GILD), founder of ARCA Discovery and now add to that list winner of the Pharmaceutical Research and Manufacturers of America (PhRMA) 2008 Discoverers Award - Clinical Trial Exceptional Services Award. The distinguished award was given for discoveries made in the early 1980’s where Dr. Bristow found the failing human heart was subjected to harmful amounts of increased adrenergic activity, and the logical therapeutic response to that activity was beta-blockade; as well as for being the Principal Investigator and Chair of the Phase II and Phase III trials for Coreg (carvedilol) where Dr. Bristow’s work also helped to characterize the receptor and molecular profiles of the drug in the human heart. Coreg a medication by GlaxoSmithKline (NYSE: GSK) was the first beta-blocker approved by the FDA for the treatment of heart failure.

PhRMA represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry-wide research and investment reached a record $55.2 billion in 2006.

***NOTE*** Take a look at the new Boulder Biotech Company Tree (HERE)!
***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

Saturday, October 20, 2007

Gilead Racks Up Quarterly Record


Gilead (NASDAQ: GILD) announced total revenues for 3Q07 of $1.06B, up 41% percent compared to total revenues of $748.7MM for 3Q06, along with record product sales of $962MM, up 44% over 3Q06! An amazing 90-day run, but what I am most interested in is how is Letaris® (ambrisentan) faring?

Now don’t quote me here because I am unable to recall/validate my sources (and I feel awful about that) but from what I have heard that with a field sales team focusing on large PAH centers Letairis® did about $6MM in its first quarter of sales and a forecast of ~$15MM for '07. The parity pricing with rival Actelion Pharma's Tracleer® (~40K/yr) has aided with reimbursement by Medicaid in 49 states, a strong label, and 9 of the top 20 managed care plans have given approval; combine these elements and Letairis should have a potent 2008 and aid a lot of people in the process. After perusing some of the PAH message boards this appears to be the tone…

"it [Letairis®] is doing wonders. I didn’t feel that way with Ventavis like many said I would but when I added Letairis I feel great. I am all over the house cleaning and playing with my kids and walking to the stores even Walmart. I'll let you know how my six minute walk and echo or rhc come out because I am doing so well they want to check those lovely numbers because that’s what counts. I hope it works for you as well as its doing for me at this point. I am a class 3 but by me just walking 2 minutes my sats didn’t drop and I wasn’t out of breath, he says its possible I'm a class 2 which would be great."

"It is amazing how much better I feel. Some days I feel almost normal. Less side effects for me than the Tracleer."

If you enjoyed this post get free email updates (here).

Tuesday, June 19, 2007

FDA Approval for Letairis (Ambrisentan)!!!


You can hear the champagne corks popping from Westminster, CO to Foster City, CA as the FDA late Friday approved Gilead's (Myogen) Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension (PAH). There are up to an estimated 90,000 people in the US suffering from PAH, a disease where blood pressure is raised due to constricting lung vessels which may lead to heart failure. Letairis® is an endothelin receptor antagonist, and works by relaxing the blood vessels. Plans are to launch US sales this week and via a co-marketing agreement with GlaxoSmithKline filing for approval for ROW sales and marketing are underway.

Letairis® approval is certainly a feather in the cap for the Colorado bio-ecosystem. The people, the science and the supporters worked long (an understatement) and hard (another understatement) to bring this drug to market. It will be exciting to see if this talented group of individuals will roll up their sleeves and do it again. That is where the true magic happens towards building a vibrant biocluster filled with serial entrepreneurs mentoring to first timers.

Friday, February 16, 2007

Ambrisentan Moving Closer to Approval


Happily tracking the progress of Gilead Sciences, Inc. (NASDAQ: GILD) Ambrisentan asset; for the treatment of pulmonary arterial hypertension. Gilead’s recent announcement that the FDA has accepted for filing and granted a priority review for the NDA is exciting news for the Colorado bio-scape. This approval may result in an accelerated review with an expectation of a 18 June 2007 review date. Recall that Gilead recently acquired Westminster, CO based Myogen for $2.5B.